Technical Analysis for NERV - Minerva Neurosciences, Inc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Lower Bollinger Band Walk | Weakness | 0.00% | |
Gapped Up | Strength | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
New 52 Week Closing Low | Bearish | 0.95% | |
Lower Bollinger Band Walk | Weakness | 0.95% | |
Inside Day | Range Contraction | 0.95% | |
Below Lower BB | Weakness | 0.95% | |
Down 3 Days in a Row | Weakness | 0.95% | |
Lower Bollinger Band Touch | Weakness | 0.95% |
Alert | Time |
---|---|
Gap Up Closed | about 20 hours ago |
60 Minute Opening Range Breakdown | about 20 hours ago |
Fell Below Previous Day's Low | about 20 hours ago |
Reversed from Up | about 20 hours ago |
Gap Up Partially Closed | about 22 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/05/2024
Minerva Neurosciences, Inc Description
Minerva Neurosciences, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidates that have completed Phase IIa trials comprise MIN-101, an antagonist on 5-HT2A and sigma2 receptors for the treatment of patients with schizophrenia; and MIN-117, an antagonist on the 5-HT1A receptor, and inhibitor of serotonin and dopamine reuptake for the treatment of major depressive disorder. It is also developing MIN-202, a selective orexin 2 receptor antagonist that is in Phase Ib trials for the treatment of primary and secondary insomnia; and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, which is in investigational new drug-enabling studies for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences Inc. in 2013. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Neuroscience Parkinson's Disease Psychoactive Drugs Schizophrenia Major Depressive Disorder Depressive Disorder Treatment Of Parkinson's Disease Neurochemistry Antidepressants Ketones Insomnia Treatment Of Major Depressive Disorder Central Nervous System Disease Investigational New Drug Treatment Of Central Nervous System Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 13.49 |
52 Week Low | 2.0703 |
Average Volume | 17,611 |
200-Day Moving Average | 3.13 |
50-Day Moving Average | 2.55 |
20-Day Moving Average | 2.34 |
10-Day Moving Average | 2.25 |
Average True Range | 0.13 |
RSI (14) | 31.97 |
ADX | 20.52 |
+DI | 14.00 |
-DI | 18.48 |
Chandelier Exit (Long, 3 ATRs) | 2.44 |
Chandelier Exit (Short, 3 ATRs) | 2.46 |
Upper Bollinger Bands | 2.60 |
Lower Bollinger Band | 2.08 |
Percent B (%b) | 0.08 |
BandWidth | 22.29 |
MACD Line | -0.11 |
MACD Signal Line | -0.09 |
MACD Histogram | -0.0182 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.23 | ||||
Resistance 3 (R3) | 2.22 | 2.19 | 2.21 | ||
Resistance 2 (R2) | 2.19 | 2.16 | 2.19 | 2.20 | |
Resistance 1 (R1) | 2.15 | 2.14 | 2.14 | 2.16 | 2.20 |
Pivot Point | 2.12 | 2.12 | 2.11 | 2.12 | 2.12 |
Support 1 (S1) | 2.08 | 2.09 | 2.07 | 2.09 | 2.04 |
Support 2 (S2) | 2.05 | 2.07 | 2.05 | 2.04 | |
Support 3 (S3) | 2.01 | 2.05 | 2.03 | ||
Support 4 (S4) | 2.02 |